191 related articles for article (PubMed ID: 11174119)
1. [Telomerase, a universal target in immunotherapy strategies against tumor?].
Rousseau R; Soria JC
Bull Cancer; 2000 Dec; 87(12):895-901. PubMed ID: 11174119
[TBL] [Abstract][Full Text] [Related]
2. Telomerase as a universal tumor-associated antigen for cancer immunotherapy.
Vonderheide RH
Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy targeting the telomerase reverse transcriptase.
Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
[TBL] [Abstract][Full Text] [Related]
4. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
van den Eynde B
Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
[TBL] [Abstract][Full Text] [Related]
5. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
6. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
7. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
[TBL] [Abstract][Full Text] [Related]
8. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
9. Telomerase as a universal tumor antigen for cancer vaccines.
Beatty GL; Vonderheide RH
Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939
[TBL] [Abstract][Full Text] [Related]
10. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
11. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
12. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
13. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
15. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
17. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
Vonderheide RH
Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
[TBL] [Abstract][Full Text] [Related]
18. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
[TBL] [Abstract][Full Text] [Related]
19. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
20. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
Sievers E; Albers P; Schmidt-Wolf IG; Märten A
J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]